Europe & International
For the Europe & International region, 2023 was a year of expansion marked by the launch of products in new countries and the entry in the food allergy space. Despite a challenging economic environment, the region maintained its market positions and experienced growth.
Germany, a dynamic market
The German market, which is the largest allergen immunotherapy (AIT) market worldwide, continues to structurally transform because of the Therapy Allergen Ordinance (TAO) process which ensures that only registered and clinically proven allergen treatments remain on the market. Stallergenes Greer is one of the players to offer a fully registered evidence-based AIT portfolio for key allergens.
Stallergenes Greer continued to be the fastest growing company in terms of sales values1. This performance was achieved thanks to investments made over the past years in sales force expansion to increase our share of voice, as well as in scientific educational events to cover a larger target audience.
Expanding our product portfolio and geographic footprint
Stallergenes Greer continued to expand its geographic presence in the Nordics region (Denmark, Finland, Sweden and Norway). The Group’s recently registered house dust mite and grass pollen AIT tablets Aitmyte® and Aitgrys®, received price and reimbursement approvals where submitted and will be commercialised in 2024 with the support of Stallergenes Greer’s teams.
The year was also marked by the launch of Actair®/Orylmyte® in Italy, the Netherlands, Poland, Qatar, and Spain. The Italian and Spanish markets are undergoing change brought about by “regularisation” processes which, similarly to the TAO in Germany, could lead to the market exit of non-registered AIT treatments.
The Group also made important strides in the United Kingdom with the availability of its peanut allergy oral immunotherapy (OIT), Palforzia®, the submission for registration of Oralair® with the Medicines and Healthcare Products Regulatory Agency, and the registration of Actair® in 2022.
A new commercial approach, undertaken in Japan by the Group’s partner for house dust mite AIT treatment, is bearing fruit with a rise in new patient initiation and first signs of market share gains.
Treating patients with peanut allergy
With the addition of Palforzia®, the only available oral immunotherapy treatment for patients with peanut allergy, to the portfolio, Stallergenes Greer became the first company to be present both in respiratory and food allergies.
in Austria, Germany, the United Kingdom, and Switzerland. The Europe and International teams are currently preparing the launch of Palforzia®, which will depend on price and reimbursement processes, in additional European countries.
In the future, Stallergenes Greer is committed to making Palforzia® available to an increasing number of patients. The recent findings of the Poseidon (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) Phase III study highlight the clinical significance and favourable safety profile of Palforzia® for peanutallergic children aged 1 to 3 years. The extension of indication to this age group is under assessment by health authorities.
Driving organisational growth
To better navigate the changing market landscape, the region has implemented a series of training programmes to support the development of its teams. Training on critical competencies, for both sales managers and executives, are being rolledout throughout the region to improve performance and optimise processes and resources.
By focusing on commercial excellence and developing and engaging its teams, Stallergenes Greer aims to better cater to the needs of patients and healthcare professionals.
1. Based on internal estimates
House dust mite allergy is challenging! Eviction of house dust mites is complicated as they can be found throughout a home on bedding, pillows, carpets, but also on clothing and soft toys. House dust mite allergy can be a significant issue all year round.”
CAROLINE, MOTHER OF PRUNE AND TIMOTHÉE
